Ronald Chow1, Leonard Chiu1, Rudolph Navari2, Steven Passik3, Nicholas Chiu1, Marko Popovic1, Henry Lam1, Mark Pasetka1, Edward Chow4,5, Carlo DeAngelis1. 1. Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. 2. Indiana University School of Medicine, South Bend, USA. 3. Millenium Health, San Diego, CA, USA. 4. Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. edward.chow@sunnybrook.ca. 5. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada. edward.chow@sunnybrook.ca.
Abstract
INTRODUCTION: Olanzapine is an atypical antipsychotic drug that inhibits serotonergic, dopaminergic, alpha-1 adrenergic, histaminic, and muscarinic receptors. Several phase I and II trials have been published documenting the use of olanzapine in controlling chemotherapy-induced nausea and vomiting (CINV). This review aims to summarize all phase I and II trials that reported on olanzapine for the prophylaxis of CINV. METHODS: A literature search was conducted in Ovid MEDLINE from 1946 to July week 1 2015, Embase Classic and Embase from 1947 to 2015 week 28, and the Cochrane Central Register of Controlled Trials up until June 2015. Phase I and II trials reporting on olanzapine for the prophylaxis for CINV were included if they reported on at least one of four primary endpoints: complete response (CR), complete control (CC), no nausea, and no emesis. Other endpoints of interest included the safety of olanzapine as measured by the M.D. Anderson Symptom Inventory. RESULTS: Across the seven included studies, there were a total of 201 patients. The CR across four studies was 97.2, 83.1, and 82.8 % for the acute, delayed, and overall phases, respectively. The CC for acute, delayed, and overall phases was 92.5, 87.5, and 82.5 %, respectively. The overall no nausea rate was 92.7, 71.8, and 70.6 % for the acute, delayed, and overall phases, respectively. The overall no emesis rates for the acute, delayed, and overall phases were 100, 94.5, and 90.4 %, respectively. Fatigue, drowsiness, and disturbed sleep were common side effects. CONCLUSION: Olanzapine is efficacious and safe when used as a prophylaxis for CINV.
INTRODUCTION:Olanzapine is an atypical antipsychotic drug that inhibits serotonergic, dopaminergic, alpha-1 adrenergic, histaminic, and muscarinic receptors. Several phase I and II trials have been published documenting the use of olanzapine in controlling chemotherapy-induced nausea and vomiting (CINV). This review aims to summarize all phase I and II trials that reported on olanzapine for the prophylaxis of CINV. METHODS: A literature search was conducted in Ovid MEDLINE from 1946 to July week 1 2015, Embase Classic and Embase from 1947 to 2015 week 28, and the Cochrane Central Register of Controlled Trials up until June 2015. Phase I and II trials reporting on olanzapine for the prophylaxis for CINV were included if they reported on at least one of four primary endpoints: complete response (CR), complete control (CC), no nausea, and no emesis. Other endpoints of interest included the safety of olanzapine as measured by the M.D. Anderson Symptom Inventory. RESULTS: Across the seven included studies, there were a total of 201 patients. The CR across four studies was 97.2, 83.1, and 82.8 % for the acute, delayed, and overall phases, respectively. The CC for acute, delayed, and overall phases was 92.5, 87.5, and 82.5 %, respectively. The overall no nausea rate was 92.7, 71.8, and 70.6 % for the acute, delayed, and overall phases, respectively. The overall no emesis rates for the acute, delayed, and overall phases were 100, 94.5, and 90.4 %, respectively. Fatigue, drowsiness, and disturbed sleep were common side effects. CONCLUSION:Olanzapine is efficacious and safe when used as a prophylaxis for CINV.
Entities:
Keywords:
Chemotherapy-induced nausea and vomiting; Efficacy; Olanzapine; Prophylaxis; Safety
Authors: Rudolph M Navari; Lawrence H Einhorn; Patrick J Loehrer; Steven D Passik; Jake Vinson; John McClean; Naveed Chowhan; Nasser H Hanna; Cynthia S Johnson Journal: Support Care Cancer Date: 2007-03-21 Impact factor: 3.603
Authors: Helen S Mayberg; J Arturo Silva; Steven K Brannan; Janet L Tekell; Roderick K Mahurin; Scott McGinnis; Paul A Jerabek Journal: Am J Psychiatry Date: 2002-05 Impact factor: 18.112
Authors: Steven D Passik; Rudolph M Navari; Sin-Ho Jung; Cindy Nagy; Jake Vinson; Kenneth L Kirsh; Patrick Loehrer Journal: Cancer Invest Date: 2004 Impact factor: 2.176
Authors: Rudolph M Navari; Lawrence H Einhorn; Steven D Passik; Patrick J Loehrer; Cynthia Johnson; M L Mayer; J McClean; Jake Vinson; W Pletcher Journal: Support Care Cancer Date: 2005-02-08 Impact factor: 3.603
Authors: F P Bymaster; D O Calligaro; J F Falcone; R D Marsh; N A Moore; N C Tye; P Seeman; D T Wong Journal: Neuropsychopharmacology Date: 1996-02 Impact factor: 7.853
Authors: Steven D Passik; Jeremy Lundberg; Kenneth L Kirsh; Dale Theobald; Kathleen Donaghy; Elizabeth Holtsclaw; Maureen Cooper; William Dugan Journal: J Pain Symptom Manage Date: 2002-06 Impact factor: 3.612
Authors: Ronald Chow; David G Warr; Rudolph M Navari; May Tsao; Marko Popovic; Leonard Chiu; Milica Milakovic; Henry Lam; Carlo DeAngelis Journal: Support Care Cancer Date: 2018-05-23 Impact factor: 3.603
Authors: S Carnio; D Galetta; V Scotti; D L Cortinovis; A Antonuzzo; S Pisconti; A Rossi; O Martelli; F L Cecere; A Lunghi; A Del Conte; E S Montagna; J Topulli; D Pelizzoni; S G Rapetti; M Gianetta; M V Pacchiana; V Pegoraro; N Cataldo; E Bria; S Novello Journal: Support Care Cancer Date: 2017-12-21 Impact factor: 3.603
Authors: Ronald Chow; Crystal Valdez; Natalie Chow; Daniel Zhang; James Im; Emily Sodhi; Michael Lock Journal: Support Care Cancer Date: 2020-01-08 Impact factor: 3.603
Authors: J Flank; T Schechter; P Gibson; D L Johnston; A D Orsey; C Portwine; L Sung; L L Dupuis Journal: Support Care Cancer Date: 2017-08-30 Impact factor: 3.603
Authors: Abdullah A Alhifany; Ali McBride; Abdulaali R Almutairi; Ejaz Cheema; Alaa Shahbar; Yasser Alatawi; Adnan S Alharbi; Hani Babiker; Karen MacDonald; Matti Aapro; Ivo Abraham Journal: Support Care Cancer Date: 2019-12-10 Impact factor: 3.603